The accuracy of Ki67-trained PTM-NET in the segmentation of tumour and non-tumour regions in breast cancer tissues labelled with two other nuclear markers clinically relevant to breast cancer treatment, namely ER and PR, was assessed. This evidence concerns the gene MKI67 and breast carcinoma.